Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hua Medicine Partners with GemVCare on Real-World Clinical Study for Dorzagliatin in Precision Diabetes Management

Fineline Cube Jul 6, 2026
Company Deals

CSPC Pharmaceutical’s Megalith Subsidiary Enters $1.77 Billion siRNA Collaboration with AstraZeneca for Novel RNAi Therapeutics

Fineline Cube Jul 3, 2026
Company Deals

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy

Fineline Cube Jul 2, 2026
Company Deals Digital

Insilico Medicine and Takeda Launch $600M Strategic AI Drug Discovery Collaboration – Pharma.AI Platform to Drive Candidate Identification for High-Potential Therapeutic Targets

Fineline Cube Jul 2, 2026
Company Deals

Nona Biosciences and Lonza Forge Strategic Alliance to Develop Best-in-Class Blood-Brain Barrier Penetration Technology for CNS Therapeutics

Fineline Cube Jul 2, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Sino Biopharmaceutical Submits China Marketing Application for World’s First Intra-Incisional Long-Acting Ropivacaine Analgesic

Fineline Cube Jul 6, 2026
Company Drug

Shaanxi Micot Enrolls First Patient in Phase Ib/II Clinical Trial of MT1002 for Acute Ischemic Stroke Treatment

Fineline Cube Jul 6, 2026
Company

Siemens Healthineers Q3 2022 Results Show Decline Amid COVID-19 Impact

Fineline Cube Aug 12, 2022

Siemens Healthineers AG (ETR: SHL) released its financial results for the fiscal year Q3 2022...

R&D

Chinese Researchers Map Cancer Genomic Alterations in 10,000 Patients

Fineline Cube Aug 12, 2022

A team of Chinese researchers led by Wang Minghui at Sun Yat-sen University has conducted...

Company Deals

Longwood Valley Medtech Partners with J&J MedTech on Digital Surgery Biosystem

Fineline Cube Aug 12, 2022

Beijing-based Longwood Valley Medtech has entered into an in-depth partnership with US major Johnson &...

Company Deals

Elite Pharma Raises RMB100m in Series B Financing for Drug Delivery Tech

Fineline Cube Aug 12, 2022

Shanghai-based Elite Pharmaceutical Technology Inc. has reportedly raised nearly RMB100 million (USD14.8 million) in a...

Company Deals

WuXi ATU Licenses TESSA Technology to Janssen Biotech for AAV Production

Fineline Cube Aug 12, 2022

WuXi Advanced Therapies (WuXi ATU), the gene and cell therapy-focused CTDMO unit of WuXi Apptec,...

Company Deals

Medlander Medical Technology’s IPO Raises RMB 1 billion on Shanghai’s STAR Board

Fineline Cube Aug 12, 2022

Medlander Medical Technology Inc., a leading Chinese manufacturer of pelvic floor rehabilitation equipment, has completed...

Company Drug

InnoCare Pharma’s Orelabrutinib sNDA Accepted for Marginal Zone Lymphoma

Fineline Cube Aug 12, 2022

InnoCare Pharma (HKG: 9969) announced that a supplemental New Drug Application (sNDA) for its Bruton’s...

Company Deals

TianShiWei Raises Tens of Millions in Series A for Medical Aesthetics Expansion

Fineline Cube Aug 12, 2022

hina-based Wuhan TianShiWei Biotechnology Co., Ltd has reportedly raised tens of millions of renminbi in...

Company Deals

BeiGene Partners with Jilin Cancer Hospital for Cancer Drug Development

Fineline Cube Aug 12, 2022

China-based BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) has entered into a clinical study partnership...

Policy / Regulatory

China Ramps Up Monitoring of Clinically Shortage Drugs Involving 109 Varieties

Fineline Cube Aug 12, 2022

The Ministry of Industry and Information Technology (MIIT), National Health Commission (NHC), National Healthcare Security...

Company Drug

Arbele’s ARB202 Enters Phase I Trial for Advanced Gastrointestinal Cancer

Fineline Cube Aug 11, 2022

Hong Kong-based biopharma Arbele announced that its CDH17 × CD3 bispecific T-Cell engager antibody, ARB202,...

Deals Hospital

ByteDance Acquires Amcare Healthcare for USD1.5b via Xiaohe Health Unit

Fineline Cube Aug 11, 2022

ByteDance Ltd, the parent company of social media platforms TikTok and Douyin, has acquired Amcare...

Company Deals Legal / IP Policy / Regulatory

Taihu Bay Healthcare Conference Launches Wuxi IP Protection Center

Fineline Cube Aug 11, 2022

The 2022 Taihu Bay Future Healthcare Conference was held in Wuxi City, Jiangsu province, China,...

Company Deals

United Imaging Healthcare’s STAR Listing Raises USD1.85 Billion

Fineline Cube Aug 11, 2022

Shanghai-based United Imaging Healthcare (UIH) has completed an initial public offering (IPO) of 100 million...

Company Medical Device

Boston Scientific’s Rezūm System Installed in China’s Urinary Innovation Center

Fineline Cube Aug 11, 2022

US major Boston Scientific Corporation (NYSE: BSX) has jointly established the “Urinary Joint Innovation Center”...

Company Deals

Trautec Medical Raises RMB200m in Series A Financing for Recombinant Collagen R&D

Fineline Cube Aug 11, 2022

China-based Jiangsu Trautec Medical Technology Co., Ltd. has reportedly raised nearly RMB200 million (USD205.3 million)...

Drug

Zhaoke Ophthalmology Enrolls First Patient in ZKY001 Phase II TPRK Study

Fineline Cube Aug 11, 2022

China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) spin-off Zhaoke Ophthalmology Ltd (HKG: 6622) announced the...

Company Deals

Insilico Medicine Closes USD95m Series D Financing to Advance AI Drug Discovery

Fineline Cube Aug 11, 2022

Insilico Medicine, a Hong Kong-based artificial intelligence (AI)-driven drug discovery company, announced the closure of...

Company Drug

LianBio Completes Enrollment for Mavacamten Phase III Trial in oHCM

Fineline Cube Aug 11, 2022

China-based biotech LianBio (OTCMKTS: LIANY) announced that enrollment has been completed in the Phase III...

Company Deals

Huadong Medicine to Acquire 60% Stake in Wuhu Huaren for RMB 396 Million

Fineline Cube Aug 11, 2022

China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that its subsidiary, Hangzhou Zhongmei Huadong Pharmaceutical...

Posts pagination

1 … 662 663 664 … 690

Recent updates

  • Sino Biopharmaceutical Submits China Marketing Application for World’s First Intra-Incisional Long-Acting Ropivacaine Analgesic
  • Shaanxi Micot Enrolls First Patient in Phase Ib/II Clinical Trial of MT1002 for Acute Ischemic Stroke Treatment
  • China’s NMPA Unveils Comprehensive Regulatory Framework for Cell and Gene Therapy Products with Streamlined Review Pathways
  • Changchun High & New Tech Secures NMPA Clinical Approval for GenSci164 PTH1R Agonist in Hypoparathyroidism Treatment
  • Hua Medicine Partners with GemVCare on Real-World Clinical Study for Dorzagliatin in Precision Diabetes Management
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Sino Biopharmaceutical Submits China Marketing Application for World’s First Intra-Incisional Long-Acting Ropivacaine Analgesic

Company Drug

Shaanxi Micot Enrolls First Patient in Phase Ib/II Clinical Trial of MT1002 for Acute Ischemic Stroke Treatment

Others

China’s NMPA Unveils Comprehensive Regulatory Framework for Cell and Gene Therapy Products with Streamlined Review Pathways

Company Drug

Changchun High & New Tech Secures NMPA Clinical Approval for GenSci164 PTH1R Agonist in Hypoparathyroidism Treatment

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.